Economic Evaluation of Cytosponge®-Trefoil Factor 3 for Barrett's Oesophagus: A Cost-Utility Analysis

2020 ◽  
Author(s):  
Nicholas Swart ◽  
R. Maroni ◽  
Beth Muldrew ◽  
Peter Sasieni ◽  
Rebecca C. Fitzgerald ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Barrett’S Oesophagus ◽  
Trefoil Factor ◽  
Utility Analysis ◽  
Barrett's Oesophagus ◽  
Trefoil Factor 3

scholarly journals Health economic measures in schizophrenia research

2007 ◽  
Vol 191 (S50) ◽  
pp. s42-s45 ◽  
Author(s):  
Paul McCrone
Keyword(s):  
Health Economic ◽  
Economic Evaluation ◽  
Cost Utility ◽  
Outcome Data ◽  
Cost Utility Analysis ◽  
Economic Evaluations ◽  
Utility Analysis ◽  
Short Term ◽  
Effectiveness Analysis

BackgroundIt is essential in economic evaluations of schizophrenia interventions that all relevant costs are identified and measured appropriately Also of importance is the way in which cost data are combined with information on outcomesAimsTo examine the use of health economicsin evaluations of interventions for schizophreniaMethodsAreview of the key methods used to estimate costs and to link costs and outcomes was conductedResultsCosts fall on a number of different agencies and can be short term or long term. Cost-effectiveness analysis and cost-utility analysis are the most appropriate methods for combing cost and outcome dataConclusionsSchizophrenia poses a number of challenges for economic evaluation

An Economic Evaluation of Treatments for HIV-Associated Facial Lipoatrophy: A Cost-Utility Analysis

2010 ◽  
Vol 8 (5) ◽  
pp. 386-395 ◽  
Author(s):  
Sirianong Peyasantiwong ◽  
Mona R. Loutfy ◽  
Audrey Laporte ◽  
Peter C. Coyte
Keyword(s):  
Economic Evaluation ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Facial Lipoatrophy

Economic Evaluation of CAM Use

2017 ◽  
pp. 232-271
Author(s):  
Li-Chia Chen ◽  
Mayuree Tangkiatkumjai
Keyword(s):  
Decision Making ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Conventional Medicine ◽  
Kidney Diseases ◽  
Developed Countries ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Healthcare Interventions

Economic evaluation (EE) of health care interventions has been used to inform and affect policy decision-making by considering both costs and outcomes of the interventions. National guidelines in many countries consider cost-effectiveness evidence for making recommendations of healthcare interventions. In such case, EE of complementary and alternative medicine (CAM) is crucial to guide reimbursement decision-making. However, there is currently a lack of cost-effectiveness evidence of using CAM for kidney diseases. There are three types of full EEs, including a cost-benefit, cost-effectiveness, and cost-utility analysis, of which, results of cost-utility analysis is preferred and widely used by healthcare authorities in several developed countries. General approaches for EE of conventional medicine are likely to be applied to assess economic outcomes of CAM for kidney diseases. This chapter depicts the overall principles of EEs, interpretations of economic results and summaries the currently available EE for CAM.

Sign in / Sign up

Export Citation Format

Share Document